Resources
110 Results (showing 41 - 50)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 6/6/2022 (updated 3/27/2024)
Whether an opioid overdose death is unintentional or intentional (i.e., suicide), it can be difficult to disentangle. The suffering and hopelessness associated with addiction often lead to indifference to living or dying and to extreme risk taking. In this presentation, examples were described and presented from an opioid-specific suicide prevention training module that is part of the SafeSide Prevention learning program
Posted 6/3/2022 (updated 3/27/2024)
This session highlighted the ways in which data from RCORP consortia are used, how service capacity and access have changed, and whether there is evidence that the health status of rural residents is improving. Additional data on telehealth utility, COVID-19 vaccination efforts, and drivers of Medication-Assisted Treatment (MAT) retention was highlighted.
Posted 5/25/2022 (updated 3/27/2024)
CDC’s Division of Overdose Prevention has developed an interactive data visualization tool, the DOSE Dashboard, which displays current nonfatal overdose data. The nonfatal drug overdose data on this dashboard are from CDC’s Drug Overdose Surveillance and Epidemiology (DOSE) system, which captures electronic health record information in syndromic surveillance data systems. DOSE data can be used to compare monthly and annual trends in nonfatal drug overdose-related ED visits by drug type (i.e., all drugs, all opioids, heroin, and all stimulants), state, and sex and age group.
Posted 4/12/2022 (updated 3/27/2024)
Since 1999, an estimated 841,000 people in the U.S. have died from a drug overdose. Beginning in March 2020, the COVID-19 pandemic significantly exacerbated the overdose crisis resulting in a 30% increase in 2020 compared to 2019. The majority of overdose deaths in the U.S. involve opioids, including nearly 71% of all overdose deaths in 2019.3 Despite high rates of overdose across the nation, overdose and overdose death are preventable. However, people at risk of overdose often face significant challenges accessing treatment and navigating systems of care. Local and state health departments are well-suited to lead and support efforts to prevent and respond to overdose and to link people to evidence-based treatment and services. Peer support services (PSS) are a valuable component of a growing number of overdose response and linkage to care initiatives that can be implemented and supported by local and state health departments.
Posted 4/12/2022 (updated 3/27/2024)
Describes the work of 26 2018-2021 Rural Health Opioid Program (RHOP) grantees in addressing the opioid epidemic through community-based consortiums. Highlights each project's achievements and identifies common themes of program impact.
Posted 4/12/2022 (updated 3/27/2024)
OMNI Institute, in partnership with the JBS RCORP-TA team, had five sessions of the Data Learning Collaborative (LC).
Posted 3/23/2022 (updated 3/27/2024)
The JBS evaluation team will review and provide guidance on the PIMS measures that are most problematic for grantees and the new PIMS measures that are pending OMB approval. They will also highlight ways that consortiums can use their data dashboards to highlight successes and areas for improvement as they work to obtain funding and motivate and engage stakeholders.
Posted 3/16/2022 (updated 3/27/2024)
Background: Sharp exacerbations of the US overdose crisis are linked to polysubstance use of synthetic compounds. Xylazine is a veterinary tranquilizer, long noted in the street opioid supply of Puerto Rico, and more recently Philadelphia. Yet its national trends, geographic distribution, and health risks are poorly characterized. Methods: In this sequential mixed-methods study, xylazine was increasingly observed by ethnographers in Philadelphia among drug-sellers and people who inject drugs (PWID). Subsequently, we systematically searched for records describing xylazine-present overdose mortality across the US and assessed time trends and overlap with other drugs
Posted 2/9/2022 (updated 3/26/2024)
HRSA and JBS have developed guidance to assist your RCORP data collection and Performance Improvement Measurement System (PIMS) reporting efforts. These measures are pending OMB clearance and are subject to revision. This page contains the RCORP data collection resources for the Psychostimulant Support grantees only.
These documents will be updated as new guidance or data sources are identified. We encourage you to bookmark this page so you have the latest version available. Please send any measure-related questions to your HRSA Project Officer or email: rcorp-eval@jbsinternational.com.
Posted 1/26/2022 (updated 3/26/2024)
The Centers for Disease Control and Prevention (CDC) looked at data from six states mandated to report on neonatal abstinence syndrome (NAS), a condition that occurs when newborn babies experience withdrawal from drugs. A previous study of these states – Arizona, Florida, Georgia, Kentucky, Tennessee, and Virginia – indicated that the reporting helped determine the prevalence of NAS and identify communities more severely affected. The current report is based on answers to a follow-up questionnaire given to epidemiologists and birth defects program managers from the same six states.